Genetic mutations causing SLC19A2 dysfunction can specifically result in outcomes such as megaloblastic anemia (TRMA), sensorineural hearing loss, hyperglycemia, and diabetes mellitus [16]. Here, SLC19A2 is linked to thiamine-responsive megaloblastic anemia syndrome.